Revenue $3.73B, up 5.8% on a year earlier. Diagnostics Laboratories Revenue $2.90B, up 5.5%. Diluted EPS $3.64 against $2.84.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $3.73B | $3.54B | $3.53B | +5.8% |
| Operating income | $451.60M | $380.80M | $394.50M | +14.5% |
| Net income | $299.10M | $278.00M | $238.30M | +25.5% |
| Diluted EPS | $3.64 | $3.35 | $2.84 | |
| Operating cash flow | $445.50M | $191.50M | $620.60M | -28.2% |
| Capital expenditures | -$131.60M | -$121.00M | -$77.90M | |
| Free cash flow | $313.90M | $70.50M | $542.70M | -42.2% |
| Dividend per share | $0.72 | $0.72 | $0.72 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Diagnostics Laboratories Revenue | $2.90B | $2.75B | +5.5% |
| Revenue Growth | 5.8% | 9.51% | |
| Covance Drug Development Revenue | $836.20M | $784.80M | +6.5% |
| Backlog at end of quarter | $8.73B | $8.71B | +0.2% |
| Revenue per requisition growth | 2.5% | 4% | |
| Net Book-to-Bill Ratio | 1 | 1.11 | -9.9% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Labcorp Holdings (LH) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/LH/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
